Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
22.27
-2.31 (-9.40%)
At close: Apr 23, 2026, 4:00 PM EDT
22.43
+0.16 (0.72%)
After-hours: Apr 23, 2026, 7:55 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
17.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | -56.23M | -98.49% |
| Dec 31, 2019 | 57.09M | - | - |
| Jan 31, 2019 | 57.09M | 39.54M | 225.24% |
| Jan 31, 2018 | 17.55M | 14.65M | 505.12% |
| Jan 31, 2017 | 2.90M | - | - |
| Jan 31, 2016 | - | - | - |
| Jan 31, 2015 | - | - | - |
| Jan 31, 2014 | - | - | - |
| Jan 31, 2013 | 2.88M | 2.57M | 847.80% |
| Jan 31, 2010 | 303.40K | 37.67K | 14.18% |
| Jan 31, 2009 | 265.73K | -5.76M | -95.59% |
| Jan 31, 2008 | 6.03M | 4.00M | 197.42% |
| Jan 31, 2007 | 2.03M | 1.08M | 114.52% |
| Jan 31, 2006 | 944.36K | 731.95K | 344.60% |
| Jan 31, 2005 | 212.41K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| Genmab | 3.72B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
| Insmed | 606.42M |
SMMT News
- 15 days ago - Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst - Benzinga
- 27 days ago - Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 - Business Wire
- 2 months ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - Business Wire
- 2 months ago - Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 - Business Wire
- 2 months ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Business Wire
- 3 months ago - Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) - Business Wire